{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T03:13:00Z","timestamp":1785553980206,"version":"3.56.0"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008666","name":"Fundaci\u00f3 la Marat\u00f3 de TV3","doi-asserted-by":"publisher","award":["PI049956"],"award-info":[{"award-number":["PI049956"]}],"id":[{"id":"10.13039\/100008666","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["RYC2024-050099-I"],"award-info":[{"award-number":["RYC2024-050099-I"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008431","name":"Consejer\u00eda de Educaci\u00f3n, Junta de Castilla y Le\u00f3n","doi-asserted-by":"publisher","award":["BU-103-25"],"award-info":[{"award-number":["BU-103-25"]}],"id":[{"id":"10.13039\/501100008431","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019629","name":"Universidad de Burgos","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100019629","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Endometriosis is a chronic inflammatory disease characterized by the presence of endometrial-like tissue outside the uterine cavity. It affects approximately 10\u201315% of women of reproductive age globally and is characterized by heterogeneous symptoms with chronic pelvic pain, dysmenorrhea, and infertility being the most common. Although pharmacological treatments are available to manage its symptoms, many women either do not respond to these therapies or experience adverse drug reactions (ADRs) that outweigh the original symptoms of endometriosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Rationale\/Objectives<\/jats:title>\n                    <jats:p>The aim of this review is to provide a comprehensive overview of endometriosis and to identify pharmacogenetic markers that might influence drug response in its treatment and management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes<\/jats:title>\n                    <jats:p>Current research highlights a critical gap in pharmacogenetic biomarkers for endometriosis treatment, limiting the potential for personalized therapeutic strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Wider Implications<\/jats:title>\n                    <jats:p>Integrative multi-omics approaches combining genetic, inflammatory, and hormonal profiles may enhance patient stratification and optimize individualized care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11095-026-04049-9","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T23:43:25Z","timestamp":1771976605000},"page":"605-618","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["An Overview of Endometriosis and Potential Pharmacogenetic Targets"],"prefix":"10.1007","volume":"43","author":[{"given":"Noelia","family":"P\u00e9rez-G\u00f3mez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda \u00c1ngeles","family":"Mart\u00ednez-Zamora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Carmona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Novalbos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Abad-Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dora","family":"Koller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1660-3135","authenticated-orcid":false,"given":"Miriam","family":"Saiz-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"issue":"379","key":"4049_CR1","doi-asserted-by":"publisher","first-page":"e070750","DOI":"10.1136\/bmj-2022-070750","volume":"14","author":"AW Horne","year":"2022","unstructured":"Horne AW, Missmer SA. Pathophysiology, diagnosis, and management of endometriosis. BMJ. 2022;14(379):e070750.","journal-title":"BMJ"},{"issue":"2","key":"4049_CR2","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1093\/humrep\/dew293","volume":"32","author":"NP Johnson","year":"2017","unstructured":"Johnson NP, Hummelshoj L, Adamson GD, Keckstein J, Taylor HS, Abrao MS, et al. World Endometriosis Society consensus on the classification of endometriosis. Hum Reprod. 2017;32(2):315\u201324.","journal-title":"Hum Reprod"},{"issue":"2","key":"4049_CR3","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1055\/s-2003-41326","volume":"21","author":"RZ Spaczynski","year":"2003","unstructured":"Spaczynski RZ, Duleba AJ. Diagnosis of endometriosis. Semin Reprod Med. 2003;21(2):193\u2013208.","journal-title":"Semin Reprod Med"},{"issue":"5","key":"4049_CR4","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1111\/1471-0528.14838","volume":"125","author":"M Hirsch","year":"2018","unstructured":"Hirsch M, Begum MR, Paniz \u00c9, Barker C, Davis CJ, Duffy J. Diagnosis and management of endometriosis: a systematic review of international and national guidelines. BJOG. 2018;125(5):556\u201364.","journal-title":"BJOG"},{"issue":"5","key":"4049_CR5","doi-asserted-by":"publisher","first-page":"4254","DOI":"10.3390\/ijms24054254","volume":"24","author":"J Lamceva","year":"2023","unstructured":"Lamceva J, Uljanovs R, Strumfa I. The main theories on the pathogenesis of endometriosis. Int J Mol Sci. 2023;24(5):4254.","journal-title":"Int J Mol Sci"},{"issue":"13","key":"4049_CR6","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1056\/NEJMra1810764","volume":"382","author":"KT Zondervan","year":"2020","unstructured":"Zondervan KT, Becker CM, Missmer SA. Endometriosis. N Engl J Med. 2020;382(13):1244\u201356.","journal-title":"N Engl J Med"},{"issue":"8","key":"4049_CR7","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1080\/09513590.2019.1590546","volume":"35","author":"X Wen","year":"2019","unstructured":"Wen X, Xiong Y, Qu X, Jin L, Zhou C, Zhang M, et al. The risk of endometriosis after exposure to endocrine-disrupting chemicals: a meta-analysis of 30 epidemiology studies. Gynecol Endocrinol. 2019;35(8):645\u201350.","journal-title":"Gynecol Endocrinol"},{"issue":"1","key":"4049_CR8","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12974-020-01752-1","volume":"17","author":"Y Wei","year":"2020","unstructured":"Wei Y, Liang Y, Lin H, Dai Y, Yao S. Autonomic nervous system and inflammation interaction in endometriosis-associated pain. J Neuroinflammation. 2020;17(1):80.","journal-title":"J Neuroinflammation"},{"issue":"2","key":"4049_CR9","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1080\/17441692.2014.986159","volume":"10","author":"MD Cottingham","year":"2015","unstructured":"Cottingham MD. The makings of a modern epidemic: endometriosis, gender, and politics. Glob Public Health. 2015;10(2):273\u20134.","journal-title":"Glob Public Health"},{"key":"4049_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2147\/IJGM.S261139","volume":"14","author":"SA Missmer","year":"2021","unstructured":"Missmer SA, Tu FF, Agarwal SK, Chapron C, Soliman AM, Chiuve S, et al. Impact of endometriosis on life-course potential: a narrative review. Int J Gen Med. 2021;14:9\u201325.","journal-title":"Int J Gen Med"},{"issue":"1","key":"4049_CR11","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.fertnstert.2007.11.020","volume":"91","author":"R Greene","year":"2009","unstructured":"Greene R, Stratton P, Cleary SD, Ballweg ML, Sinaii N. Diagnostic experience among 4,334 women reporting surgically diagnosed endometriosis. Fertil Steril. 2009;91(1):32\u20139.","journal-title":"Fertil Steril"},{"issue":"3","key":"4049_CR12","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1080\/13697137.2019.1578743","volume":"22","author":"L Kiesel","year":"2019","unstructured":"Kiesel L, Sourouni M. Diagnosis of endometriosis in the 21st century. Climacteric. 2019;22(3):296\u2013302.","journal-title":"Climacteric"},{"issue":"4","key":"4049_CR13","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.fertnstert.2014.02.012","volume":"101","author":"Practice Committee of the American Society for Reproductive Medicine","year":"2014","unstructured":"Practice Committee of the American Society for Reproductive Medicine. Treatment of pelvic pain associated with endometriosis: a committee opinion. Fertil Steril. 2014;101(4):927\u201335.","journal-title":"Fertil Steril"},{"issue":"2","key":"4049_CR14","doi-asserted-by":"publisher","first-page":"hoac009","DOI":"10.1093\/hropen\/hoac009","volume":"2022","author":"CM Becker","year":"2022","unstructured":"Becker CM, Bokor A, Heikinheimo O, Horne A, Jansen F, Kiesel L, et al. ESHRE guideline: endometriosis. Hum Reprod Open. 2022;2022(2):hoac009.","journal-title":"Hum Reprod Open"},{"key":"4049_CR15","unstructured":"National Guideline Alliance (UK). Endometriosis: diagnosis and management [Internet]. London: National Institute for Health and Care Excellence (NICE); 2017 [cited 2025 Oct 16]. (National Institute for Health and Care Excellence: Guidelines). Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK453273\/"},{"issue":"5","key":"4049_CR16","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.3390\/jcm10051085","volume":"10","author":"J Donnez","year":"2021","unstructured":"Donnez J, Dolmans MM. Endometriosis and medical therapy: from progestogens to progesterone resistance to gnrh antagonists: a review. J Clin Med. 2021;10(5):1085.","journal-title":"J Clin Med"},{"issue":"15","key":"4049_CR17","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1080\/14656566.2017.1381086","volume":"18","author":"L Buggio","year":"2017","unstructured":"Buggio L, Somigliana E, Barbara G, Frattaruolo MP, Vercellini P. Oral and depot progestin therapy for endometriosis: towards a personalized medicine. Expert Opin Pharmacother. 2017;18(15):1569\u201381.","journal-title":"Expert Opin Pharmacother"},{"issue":"11","key":"4049_CR18","doi-asserted-by":"publisher","first-page":"769","DOI":"10.3109\/09513590.2014.950646","volume":"30","author":"S Angioni","year":"2014","unstructured":"Angioni S, Cofelice V, Pontis A, Tinelli R, Socolov R. New trends of progestins treatment of endometriosis. Gynecol Endocrinol. 2014;30(11):769\u201373.","journal-title":"Gynecol Endocrinol"},{"issue":"4","key":"4049_CR19","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/17425255.2018.1461840","volume":"14","author":"F Barra","year":"2018","unstructured":"Barra F, Scala C, Ferrero S. Current understanding on pharmacokinetics, clinical efficacy and safety of progestins for treating pain associated to endometriosis. Expert Opin Drug Metab Toxicol. 2018;14(4):399\u2013415.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"10","key":"4049_CR20","doi-asserted-by":"publisher","first-page":"3388","DOI":"10.3390\/jcm12103388","volume":"12","author":"M Garc\u00eda-S\u00e1enz","year":"2023","unstructured":"Garc\u00eda-S\u00e1enz M, Ibarra-Salce R, Pozos-Varela FJ, Mena-Ureta TS, Flores-Villag\u00f3mez S, Santana-Mata M, et al. Understanding progestins: from basics to clinical applicability. J Clin Med. 2023;12(10):3388.","journal-title":"J Clin Med"},{"key":"4049_CR21","first-page":"595","volume":"7","author":"L Mu\u00f1oz-Hernando","year":"2015","unstructured":"Mu\u00f1oz-Hernando L, Mu\u00f1oz-Gonzalez JL, Marqueta-Marques L, Alvarez-Conejo C, Tejerizo-Garc\u00eda \u00c1, Lopez-Gonzalez G, et al. Endometriosis: alternative methods of medical treatment. Int J Womens Health. 2015;7:595\u2013603.","journal-title":"Int J Womens Health"},{"issue":"5","key":"4049_CR22","doi-asserted-by":"publisher","first-page":"bnaa012","DOI":"10.1210\/endrev\/bnaa012","volume":"41","author":"MS Islam","year":"2020","unstructured":"Islam MS, Afrin S, Jones SI, Segars J. Selective progesterone receptor modulators-mechanisms and therapeutic Utility. Endocr Rev. 2020;41(5):bnaa012.","journal-title":"Endocr Rev"},{"issue":"3","key":"4049_CR23","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1039\/D4TB01755B","volume":"13","author":"Y Peng","year":"2025","unstructured":"Peng Y, Zhang M, Yan J, Wang R, Xin Y, Zheng X, et al. Emerging bioengineering breakthroughs in precision diagnosis and therapy for endometriosis and adenomyosis. J Mater Chem B. 2025;13(3):742\u201362.","journal-title":"J Mater Chem B"},{"issue":"1","key":"4049_CR24","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1517\/14728214.9.1.167","volume":"9","author":"L Fedele","year":"2004","unstructured":"Fedele L, Berlanda N. Emerging drugs for endometriosis. Expert Opin Emerg Drugs. 2004;9(1):167\u201377.","journal-title":"Expert Opin Emerg Drugs"},{"issue":"3","key":"4049_CR25","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.fertnstert.2012.07.1120","volume":"98","author":"SR Soares","year":"2012","unstructured":"Soares SR, Mart\u00ednez-Varea A, Hidalgo-Mora JJ, Pellicer A. Pharmacologic therapies in endometriosis: a systematic review. Fertil Steril. 2012;98(3):529\u201355.","journal-title":"Fertil Steril"},{"key":"4049_CR26","doi-asserted-by":"crossref","unstructured":"Brown J, Crawford TJ, Datta S, Prentice A. Oral contraceptives for pain associated with endometriosis. Cochrane gynaecology and fertility group, editor. Cochrane Database Syst Rev [Internet]. 2018 [cited 2025 Nov 14]; 2018(5). Available from: http:\/\/doi.wiley.com\/10.1002\/14651858.CD001019.pub3.","DOI":"10.1002\/14651858.CD001019.pub3"},{"issue":"1","key":"4049_CR27","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1097\/00003081-200103000-00010","volume":"44","author":"RT Burkman","year":"2001","unstructured":"Burkman RT. Oral contraceptives: current status. Clin Obstet Gynecol. 2001;44(1):62\u201372.","journal-title":"Clin Obstet Gynecol"},{"issue":"4","key":"4049_CR28","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/(SICI)1520-6394(1998)7:4<171::AID-DA5>3.0.CO;2-D","volume":"7","author":"JK Warnock","year":"1998","unstructured":"Warnock JK, Bundren JC, Morris DW. Depressive symptoms associated with gonadotropin-releasing hormone agonists. Depress Anxiety. 1998;7(4):171\u20137.","journal-title":"Depress Anxiety"},{"key":"4049_CR29","doi-asserted-by":"publisher","first-page":"309","DOI":"10.2147\/IJWH.S442357","volume":"16","author":"ER Othman","year":"2024","unstructured":"Othman ER, Al-Hendy A, Mostafa R, Lambalk CB, Mijatovic V. Oral GnRH antagonists in combination with estradiol and norethindrone acetate for pain relief associated with endometriosis: a review of evidence of a novel class of hormonal agents. Int J Womens Health. 2024;16:309\u201321.","journal-title":"Int J Womens Health"},{"issue":"9","key":"4049_CR30","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1080\/13543784.2021.1957830","volume":"30","author":"S Dababou","year":"2021","unstructured":"Dababou S, Garzon S, Lagan\u00e0 AS, Ferrero S, Evangelisti G, Noventa M, et al. Linzagolix: a new GnRH-antagonist under investigation for the treatment of endometriosis and uterine myomas. Expert Opin Investig Drugs. 2021;30(9):903\u201311.","journal-title":"Expert Opin Investig Drugs"},{"issue":"4","key":"4049_CR31","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1007\/s00404-022-06862-0","volume":"308","author":"L Xin","year":"2023","unstructured":"Xin L, Ma Y, Ye M, Chen L, Liu F, Hou Q. Efficacy and safety of oral gonadotropin-releasing hormone antagonists in moderate-to-severe endometriosis-associated pain: a systematic review and network meta-analysis. Arch Gynecol Obstet. 2023;308(4):1047\u201356.","journal-title":"Arch Gynecol Obstet"},{"issue":"5","key":"4049_CR32","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s40261-020-00901-x","volume":"40","author":"N Leelakanok","year":"2020","unstructured":"Leelakanok N, Methaneethorn J. A systematic review and meta-analysis of the adverse effects of levonorgestrel emergency oral contraceptive. Clin Drug Investig. 2020;40(5):395\u2013420.","journal-title":"Clin Drug Investig"},{"issue":"12","key":"4049_CR33","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/S1701-2163(16)30075-5","volume":"37","author":"R Godin","year":"2015","unstructured":"Godin R, Marcoux V. Vaginally administered danazol: an overlooked option in the treatment of rectovaginal endometriosis? J Obstet Gynaecol Can. 2015;37(12):1098\u2013103.","journal-title":"J Obstet Gynaecol Can"},{"issue":"7","key":"4049_CR34","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1111\/j.1398-9995.2011.02557.x","volume":"66","author":"ML Kowalski","year":"2011","unstructured":"Kowalski ML, Makowska JS, Blanca M, Bavbek S, Bochenek G, Bousquet J, et al. Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) - classification, diagnosis and management: review of the EAACI\/ENDA# and GA2LEN\/HANNA*: Hypersensitivity to nonsteroidal anti-inflammatory drugs. Allergy. 2011;66(7):818\u201329.","journal-title":"Allergy"},{"issue":"6","key":"4049_CR35","doi-asserted-by":"publisher","first-page":"385","DOI":"10.5001\/omj.2011.101","volume":"26","author":"A Al-Saeed","year":"2011","unstructured":"Al-Saeed A. Gastrointestinal and cardiovascular risk of nonsteroidalanti-inflammatory drugs. OMJ. 2011;26(6):385\u201391.","journal-title":"OMJ"},{"key":"4049_CR36","doi-asserted-by":"crossref","unstructured":"Zhao M, Ma J, Li M, Zhang Y, Jiang B, Zhao X, et al. Cytochrome P450 enzymes and drug metabolism in humans. IJMS. 2021;22(23):12808.","DOI":"10.3390\/ijms222312808"},{"key":"4049_CR37","doi-asserted-by":"crossref","unstructured":"Hannachi I, Chadli Z, Kerkeni E, Chaabane A, Ben-Fredj N, Boughattas N, et al. Distribution of CYP3A4 andCYP3A5 Polymorphisms and Geno type combination implicated in tacrolimus metabolism. Tunis Med [Internet]. 2024 [cited 2025 Oct 2];102(9). Available from:\u00a0https:\/\/latunisiemedicale.com\/index.php\/tunismed\/article\/view\/4969","DOI":"10.62438\/tunismed.v102i9.4969"},{"key":"4049_CR38","doi-asserted-by":"crossref","unstructured":"Li L, Yang X, Tran D, Seo SK, Lu Y. Combined oral contraceptives as victims of drug interactions. Drug Metabolism and Disposition. 2023;51(6):718\u201332.","DOI":"10.1124\/dmd.122.000854"},{"key":"4049_CR39","doi-asserted-by":"publisher","unstructured":"Sun H, Sivasubramanian R, Vaidya S, Barve A, Jarugula V. Drug\u2010drug interaction studies with oral contraceptives: Pharmacokinetic\/Pharmacodynamic and study design considerations. The Journal of Clinical Pharma[Internet]. 2020 [cited 2025 Sep 22];60(S2). Available from:\u00a0https:\/\/doi.org\/10.1002\/jcph.1765","DOI":"10.1002\/jcph.1765"},{"key":"4049_CR40","doi-asserted-by":"crossref","unstructured":"Zubiaur P, Ochoa D, G\u00e1lvez M\u00c1, Saiz-Rodriguez M, Rom\u00e1n M, Aguilar M, et al. Effect of Polymorphisms in CYP2C9 and CYP2C19 on the disposition, safety and metabolism of progesterone administrated orally or vaginally. Adv Ther. 2019;36(10):2744\u201355.","DOI":"10.1007\/s12325-019-01075-5"},{"key":"4049_CR41","unstructured":"FICHA TECNICA ORGOVYX 120 MG COMPRIMIDOS RECUBIERTOS CON PELICULA [Internet]. Agencia Espa\u00f1olade Medicamentos y productos sanitarios (CIMA).; 2025. Available from:https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/1221642001\/FT_1221642001.html"},{"key":"4049_CR42","unstructured":"U.S. Food and Drug Administration. ORILISSA (elagolix) prescribing information [Internet]. Silver Spring, MD;2018 [cited 2025 Sep 18]. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210450s000lbl.pdf"},{"key":"4049_CR43","doi-asserted-by":"crossref","unstructured":"Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI, et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid: Pharmacogenetics. 2001;11(7):597\u2013607.","DOI":"10.1097\/00008571-200110000-00006"},{"key":"4049_CR44","doi-asserted-by":"crossref","unstructured":"Niemi M. Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. Clinical Pharmacology & Therapeutics. 2003;74(4):380\u20137.","DOI":"10.1016\/S0009-9236(03)00228-5"},{"key":"4049_CR45","doi-asserted-by":"crossref","unstructured":"Daily EB, Aquilante CL. Cytochrome P450 2C8 Pharmacogenetics: A review of clinical studies. Pharmacogenomics. 2009;10(9):1489\u2013510.","DOI":"10.2217\/pgs.09.82"},{"key":"4049_CR46","unstructured":"European Medicines Agency (EMA). Yselty: EPAR \u2013 Public assessment report [Internet]. European MedicinesAgency; 2022 [cited 2025 Nov 18]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/yselty-epar-public-assessment-report_en.pdf"},{"key":"4049_CR47","doi-asserted-by":"crossref","unstructured":"Szafl ik T, Smolarz B, Mroczkowska B, Kulig B, Soja M, Romanowicz H, et al. An analysis of ESR2 and CYP19A1 Gene expression levels in women with endometriosis. In Vivo. 2020;34(4):1765\u201371.","DOI":"10.21873\/invivo.11970"},{"key":"4049_CR48","doi-asserted-by":"crossref","unstructured":"Leyland-Jones B, Gray KP, Abramovitz M, Bouzyk M, Young B, Long B, et al. CYP19A1 polymorphisms andclinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1\u201398 trial. Breast Cancer Res Treat. 2015;151(2):373\u201384.","DOI":"10.1007\/s10549-015-3378-3"},{"key":"4049_CR49","doi-asserted-by":"crossref","unstructured":"the TEXT principal investigators, Johansson H, Gray KP, Pagani O, Regan MM, Viale G, et al. Impact of CYP19A1and ESR1 variants on early-onset side effects during combined endocrine therapy in the text trial. Breast Cancer Res. 2016;18(1):110.","DOI":"10.1186\/s13058-016-0771-8"},{"key":"4049_CR50","doi-asserted-by":"crossref","unstructured":"Theken KN, Lee CR, Gong L, Caudle KE, Formea CM, Gaedigk A, et al. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and nonsteroidal anti\u2010inflammatory drugs. Clin Pharma and Therapeutics. 2020;108(2):191\u2013200.","DOI":"10.1002\/cpt.1830"},{"key":"4049_CR51","doi-asserted-by":"crossref","unstructured":"Ag\u00fandez JAG, Formea C, Gaedigk A, Garc\u00eda-Mart\u00edn E, Gong L, Grosser T, et al. Editorial: NSAIDs Pharmacogenomics. Front Pharmacol. 2021;12:798447.","DOI":"10.3389\/fphar.2021.798447"},{"key":"4049_CR52","doi-asserted-by":"crossref","unstructured":"Krasniqi V, Dimovski A, Domjanovi\u0107 IK, Bili\u0107 I, Bo\u017eina N. How polymorphisms of the cytochrome P450 genesaff ect ibuprofen and diclofenac metabolism and toxicity \/ Kako polimorfi zmi gena citokroma P450 utje\u010du nametabolizam i toksi\u010dnost ibuprofena i diklofenaka. Archives of Industrial Hygiene and Toxicology. 2016;67(1):1\u20138.","DOI":"10.1515\/aiht-2016-67-2754"},{"key":"4049_CR53","doi-asserted-by":"crossref","unstructured":"Maekawa K, Adachi M, Matsuzawa Y, Zhang Q, Kuroki R, Saito Y, et al. Structural basis of single-nucleotide polymorphisms in cytochrome P450 2C9. Biochemistry. 2017;56(41):5476\u201380.","DOI":"10.1021\/acs.biochem.7b00795"},{"key":"4049_CR54","doi-asserted-by":"crossref","unstructured":"Lopes GS, Bielinski SJ, Moyer AM, Black Iii JL, Jacobson DJ, Jiang R, et al. Sex differences in associations between CYP2D6 phenotypes and response to opioid analgesics. PGPM. 2020;13:71\u20139.","DOI":"10.2147\/PGPM.S239222"},{"key":"4049_CR55","doi-asserted-by":"crossref","unstructured":"Crews KR, Monte AA, Huddart R, Caudle KE, Kharasch ED, Gaedigk A, et al. Clinical pharmacogenetics implementation consortium guideline for CYP2D6, OPRM1, and COMT genotypes and select opioid therapy. Clin Pharma and Therapeutics. 2021;110(4):888\u201396.","DOI":"10.1002\/cpt.2149"},{"key":"4049_CR56","doi-asserted-by":"crossref","unstructured":"Ieiri I, Takane H, Otsubo K. The MDR1 (ABCB1) Gene polymorphism and its clinical implications: Clinical Pharmacokinetics. 2004;43(9):553\u201376.","DOI":"10.2165\/00003088-200443090-00001"},{"key":"4049_CR57","doi-asserted-by":"crossref","unstructured":"Magadmi R, Alyoubi R, Moshrif T, Bakhshwin D, Suliman BA, Kamel F, et al. Polymorphisms in the drug transporter Gene ABCB1 are associated with drug response in Saudi Epileptic Pediatric Patients. Biomedicines. 2023;11(9):2505.","DOI":"10.3390\/biomedicines11092505"},{"issue":"12","key":"4049_CR58","doi-asserted-by":"publisher","first-page":"660639","DOI":"10.3389\/fphar.2021.660639","volume":"29","author":"G Mej\u00eda-Abril","year":"2021","unstructured":"Mej\u00eda-Abril G, Zubiaur P, Navares-G\u00f3mez M, Villapalos-Garc\u00eda G, Rom\u00e1n M, Ochoa D, et al. Dexketoprofen Pharmacokinetics is not Significantly Altered by Genetic Polymorphism. Front Pharmacol. 2021;29(12):660639.","journal-title":"Front Pharmacol"},{"key":"4049_CR59","doi-asserted-by":"crossref","unstructured":"Reis FM, Coutinho LM, Vannuccini S, Batteux F, Chapron C, Petraglia F. Progesterone receptor ligands for thetreatment of endometriosis: the mechanisms behind therapeutic success and failure. Human Reproduction Update. 2020;26(4):565\u201385.","DOI":"10.1093\/humupd\/dmaa009"},{"key":"4049_CR60","doi-asserted-by":"crossref","unstructured":"MacLean JA, Hayashi K. Progesterone actions and resistance in gynecological disorders. Cells. 2022;11(4):647.","DOI":"10.3390\/cells11040647"},{"key":"4049_CR61","doi-asserted-by":"crossref","unstructured":"Hayashi A, Tanabe A, Kawabe S, Hayashi M, Yuguchi H, Yamashita Y, et al. Dienogest increases the progesterone receptorisoform B\/A ratio in patients with ovarian endometriosis. J Ovarian Res. 2012;5(1):31.","DOI":"10.1186\/1757-2215-5-31"},{"key":"4049_CR62","doi-asserted-by":"crossref","unstructured":"Paskulin DD, Cunha-Filho JS, Paskulin LD, Souza CAB, Ashton-Prolla P. ESR1 rs9340799 is associated with Endometriosis-related infertility and in vitro fertilization failure. Disease Markers. 2013;35:907\u201313.","DOI":"10.1155\/2013\/796290"},{"key":"4049_CR63","doi-asserted-by":"crossref","unstructured":"Liaqat I, Jahan N, Lone KP, Pakstis A, Taylor HS. Genetic polymorphisms associated with Endometriosis in Pakistani Women. Journal of Endometriosis and Pelvic Pain Disorders. 2013;5(4):134\u201343.","DOI":"10.5301\/je.5000165"},{"key":"4049_CR64","doi-asserted-by":"crossref","unstructured":"Lledo B, Hortal M, Mart\u00ednez M, Ortiz JA, Morales R, Bernabeu A. Association of estrogen and progesteronereceptor polymorphisms with idiopathic thin endometrium. Pharmacogenetics and Genomics. 2025;35(4):136\u20139.","DOI":"10.1097\/FPC.0000000000000560"},{"key":"4049_CR65","doi-asserted-by":"crossref","unstructured":"Dawidowicz M, Kula A, \u015awi\u0119tochowski P, Ostrowska Z. Assessment of the impact of PTGS1, PTGS2 and CYP2C9polymorphisms on pain, effectiveness and safety of NSAID therapies. Postepy Hig Med Dosw. 2020;74:504\u201316.","DOI":"10.5604\/01.3001.0014.5497"},{"key":"4049_CR66","doi-asserted-by":"crossref","unstructured":"Taqi MM, Faisal M, Zaman H. OPRM1 A118G polymorphisms and its role in opioid addiction: Implication on severity and treatment approaches. Pharmgenomics Pers Med. 2019;12:361\u20138.","DOI":"10.2147\/PGPM.S198654"},{"key":"4049_CR67","doi-asserted-by":"crossref","unstructured":"Peci\u00f1a M, Love T, Stohler CS, Goldman D, Zubieta JK. Effects of the Mu Opioid Receptor Polymorphism (OPRM1A118G) on pain regulation, placebo effects and associated personality trait measures. Neuropsychopharmacol. 2015;40(4):957\u201365.","DOI":"10.1038\/npp.2014.272"},{"key":"4049_CR68","doi-asserted-by":"crossref","unstructured":"Wei SY, Chen LF, Lin MW, Li WC, Low I, Yang CJ, et al. The OPRM1 A118G polymorphism modulates the descending pain modulatory system for individual pain experience in young women with primary dysmenorrhea. SciRep. 2017;7(1):39906.","DOI":"10.1038\/srep39906"},{"key":"4049_CR69","doi-asserted-by":"crossref","unstructured":"Hsu PS, Cheng CM, Chao HT, Lin MW, Li WC, Lee LC, et al. OPRM1 A118G polymorphism modulating motorpathway for pain adaptability in women with primary dysmenorrhea. Front Neurosci. 2023;17:1179851.","DOI":"10.3389\/fnins.2023.1179851"},{"key":"4049_CR70","doi-asserted-by":"crossref","unstructured":"Iyer M, Reschly EJ, Krasowski MD. Functional evolution of the pregnane X receptor. Expert Opin Drug MetabToxicol. 2006;2(3):381\u201397.","DOI":"10.1517\/17425255.2.3.381"},{"key":"4049_CR71","doi-asserted-by":"crossref","unstructured":"Kliewer SA, Goodwin B, Willson TM. The nuclear Pregnane X Receptor: A key regulator of xenobiotic metabolism. Endocrine Reviews. 2002;23(5):687\u2013702.","DOI":"10.1210\/er.2001-0038"},{"key":"4049_CR72","doi-asserted-by":"crossref","unstructured":"Skandalaki A, Sarantis P, Theocharis S. Pregnane X Receptor (PXR) polymorphisms and cancer treatment. Biomolecules. 2021;11(8):1142.","DOI":"10.3390\/biom11081142"},{"key":"4049_CR73","doi-asserted-by":"crossref","unstructured":"Lim YP, Liu CH, Shyu LJ, Huang J ding. Functional characterization of a novel polymorphism of pregnane Xreceptor, Q158K, in Chinese subjects: Pharmacogenetics and Genomics. 2005;15(5):337\u201341.","DOI":"10.1097\/01213011-200505000-00009"},{"key":"4049_CR74","doi-asserted-by":"crossref","unstructured":"White MJ, Eren F, Agirbasli D, Williams SM, Agirbasli M. SHBG gene polymorphism (rs1799941) associates with metabolic syndrome in children and adolescents. Devaney J, editor. PLoS ONE. 2015;10(2):e0116915.","DOI":"10.1371\/journal.pone.0116915"},{"key":"4049_CR75","doi-asserted-by":"crossref","unstructured":"Narinx N, David K, Walravens J, Vermeersch P, Claessens F, Fiers T, et al. Role of sex hormone-binding globulinin the free hormone hypothesis and the relevance of free testosterone in androgen physiology. Cell Mol Life Sci. 2022;79(11):543.","DOI":"10.1007\/s00018-022-04562-1"},{"key":"4049_CR76","doi-asserted-by":"crossref","unstructured":"De Andrade VT, N\u00e1cul AP, Dos Santos BR, Lecke SB, Spritzer PM, Morsch DM. Circulating and peritoneal fluidinterleukin-6 levels and gene expression in pelvic endometriosis. Experimental and Therapeutic Medicine. 2017;14(3):2317\u201322.","DOI":"10.3892\/etm.2017.4794"},{"key":"4049_CR77","doi-asserted-by":"crossref","unstructured":"Krygere L, Jukna P, Jariene K, Drejeriene E. Diagnostic potential of cytokine biomarkers in Endometriosis: Challenges and Insights. Biomedicines. 2024;12(12):2867.","DOI":"10.3390\/biomedicines12122867"},{"key":"4049_CR78","doi-asserted-by":"crossref","unstructured":"Brichant G, Laraki I, Henry L, Munaut C, Nisolle M. New Therapeutics in Endometriosis: A Review of Hormonal,Non-Hormonal, and Non-Coding RNA Treatments. IJMS. 2021;22(19):10498.","DOI":"10.3390\/ijms221910498"},{"key":"4049_CR79","doi-asserted-by":"crossref","unstructured":"Harada T, Iwabe T, Terakawa N. Role of cytokines in endometriosis. Fertility and Sterility. 2001;76(1):1\u201310.","DOI":"10.1016\/S0015-0282(01)01816-7"},{"key":"4049_CR80","doi-asserted-by":"crossref","unstructured":"Grandi G, Mueller M, Bersinger N, Papadia A, Nirgianakis K, Cagnacci A, et al. Progestin suppressedinfl ammation and cell viability of tumor necrosis factor\u2010\u03b1\u2010stimulated endometriotic stromal cells. American J RepImmunol. 2016;76(4):292\u20138.","DOI":"10.1111\/aji.12552"},{"key":"4049_CR81","doi-asserted-by":"crossref","unstructured":"Ichioka M, Mita S, Shimizu Y, Imada K, Kiyono T, Bono Y, et al. Dienogest, a synthetic progestin, down-regulates expression of CYP19A1 and inflammatory and neuroangiogenesis factors through progesterone receptorisoforms A and B in endometriotic cells. The Journal of Steroid Biochemistry and Molecular Biology. 2015;147:103\u201310.","DOI":"10.1016\/j.jsbmb.2014.12.008"},{"key":"4049_CR82","doi-asserted-by":"crossref","unstructured":"Grandi G, Mueller M, Bersinger NA, Cagnacci A, Volpe A, McKinnon B. Does dienogest influence the inflammatory response of endometriotic cells? A systematic review. Infl amm Res. 2016;65(3):183\u201392.","DOI":"10.1007\/s00011-015-0909-7"},{"key":"4049_CR83","doi-asserted-by":"crossref","unstructured":"Horie S, Harada T, Mitsunari M, Taniguchi F, Iwabe T, Terakawa N. Progesterone and progestational compoundsattenuate tumor necrosis factor alpha\u2013induced interleukin-8 production via nuclear factor kappaB inactivation inendometriotic stromal cells. Fertility and Sterility. 2005;83(5):1530\u20135.","DOI":"10.1016\/j.fertnstert.2004.11.042"},{"key":"4049_CR84","doi-asserted-by":"crossref","unstructured":"Botelho M, Hip\u00f3lito-Reis M, Fernandes AS, Martinho M, Rodrigues AR, Gouveia AM, et al. Hormonal treatment in endometriosis fails to prevent IL-6 increase and endometrium fi brosis but regulates levels of CYP17A, VEGF, andNFkB. Journal of Reproductive Immunology. 2026;173:104841.","DOI":"10.1016\/j.jri.2026.104841"},{"key":"4049_CR85","doi-asserted-by":"crossref","unstructured":"As-Sanie S, Mackenzie SC, Morrison L, Schrepf A, Zondervan KT, Horne AW, et al. Endometriosis: A review. JAMA. 2025;334(1):64.","DOI":"10.1001\/jama.2025.2975"},{"key":"4049_CR86","doi-asserted-by":"crossref","unstructured":"Kenis G, Maes M. Effects of antidepressants on the production of cytokines. Int J Neuropsychopharm. 200;5(4):401\u201312.","DOI":"10.1017\/S1461145702003164"},{"key":"4049_CR87","doi-asserted-by":"crossref","unstructured":"Venkatesha S, Dudics S, Acharya B, Moudgil K. Cytokine-modulating strategies and newer cytokine targets forarthritis therapy. IJMS. 2014;16(1):887\u2013906.","DOI":"10.3390\/ijms16010887"},{"key":"4049_CR88","doi-asserted-by":"crossref","unstructured":"Rider P, Carmi Y, Cohen I. Biologics for targeting inflammatory cytokines, clinical uses, and limitations. International Journal of Cell Biology. 2016;2016:1\u201311.","DOI":"10.1155\/2016\/9259646"},{"key":"4049_CR89","doi-asserted-by":"crossref","unstructured":"Huang L, Shi L, Li M, Yin X, Ji X. Oxidative stress in endometriosis: Sources, mechanisms and therapeuticpotential of antioxidants (Review). Int J Mol Med. 2025;55(5):1\u201311.","DOI":"10.3892\/ijmm.2025.5513"},{"key":"4049_CR90","doi-asserted-by":"crossref","unstructured":"Amreen S, Kumar P, Gupta P, Rao P. Evaluation of oxidative stress and severity of endometriosis. J Hum ReprodSci. 2019;12(1):40.","DOI":"10.4103\/jhrs.JHRS_27_17"},{"key":"4049_CR91","doi-asserted-by":"crossref","unstructured":"Carvalho LFP, Samadder AN, Agarwal A, Fernandes LFC, Abr\u00e3o MS. Oxidative stress biomarkers in patients withendometriosis: systematic review. Arch Gynecol Obstet. 2012;286(4):1033\u201340.","DOI":"10.1007\/s00404-012-2439-7"},{"key":"4049_CR92","doi-asserted-by":"crossref","unstructured":"Biasioli A, Xholli A, Previtera F, Balzano A, Capodicasa V, Tassi A, et al. Systemic Oxidative Stress in Womenwith Ovarian and Pelvic Endometriosis: Role of Hormonal Therapy. JCM. 2022;11(24):7460.","DOI":"10.3390\/jcm11247460"},{"key":"4049_CR93","doi-asserted-by":"crossref","unstructured":"Clower L, Fleshman T, Geldenhuys WJ, Santanam N. Targeting Oxidative Stress Involved in Endometriosis andIts Pain. Biomolecules. 2022;12(8):1055.","DOI":"10.3390\/biom12081055"},{"key":"4049_CR94","doi-asserted-by":"crossref","unstructured":"Li S, Fan Y, Shu C, Zhou Y, Shu J. Methyl 3,4-dihydroxybenzoate alleviates oxidative damage in granulosa cellsby activating Nrf2 antioxidant pathway. J Ovarian Res. 2024;17(1):87.","DOI":"10.1186\/s13048-024-01412-5"},{"key":"4049_CR95","doi-asserted-by":"crossref","unstructured":"Collette T, Maheux R, Mailloux J, Akoum A. Increased expression of matrix metalloproteinase-9 in the eutopicendometrial tissue of women with endometriosis. Human Reproduction. 2006;21(12):3059\u201367.","DOI":"10.1093\/humrep\/del297"},{"key":"4049_CR96","doi-asserted-by":"crossref","unstructured":"Collette T. Evidence for an increased release of proteolytic activity by the eutopic endometrial tissue in womenwith endometriosis and for involvement of matrix metalloproteinase-9. Human Reproduction. 2004;19(6):1257\u201364.","DOI":"10.1093\/humrep\/deh290"},{"key":"4049_CR97","doi-asserted-by":"crossref","unstructured":"Szamatowicz J. Matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1: a possible role inthe pathogenesis of endometriosis. Human Reproduction. 2002;17(2):284\u20138.","DOI":"10.1093\/humrep\/17.2.284"},{"key":"4049_CR98","doi-asserted-by":"crossref","unstructured":"Taylor HS, Kotlyar AM, Flores VA. Endometriosis is a chronic systemic disease: clinical challenges and novelinnovations. The Lancet. 2021;397(10276):839\u201352.","DOI":"10.1016\/S0140-6736(21)00389-5"},{"key":"4049_CR99","doi-asserted-by":"crossref","unstructured":"Matsuzaki S, Canis M. Effects of hormonal treatment on the expression of collagen type I, matrixmetalloproteinase-1, and tissue inhibitor of metalloproteinases-1 in endometriosis. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2026;316:114788.","DOI":"10.1016\/j.ejogrb.2025.114788"},{"key":"4049_CR100","doi-asserted-by":"crossref","unstructured":"Laronha H, Carpinteiro I, Portugal J, Azul A, Polido M, Petrova KT, et al. Challenges in Matrix Metalloproteinases Inhibition. Biomolecules. 2020;10(5):717.","DOI":"10.3390\/biom10050717"},{"key":"4049_CR101","doi-asserted-by":"crossref","unstructured":"Yu Y, Zhu Y, Gao M, Wang Y, Li S, Gou Y. Research progress on natural plant metabolites targeting apoptosis forendometriosis prevention and treatment: a systematic review. Front Pharmacol. 2025;16:1624569.","DOI":"10.3389\/fphar.2025.1624569"},{"key":"4049_CR102","doi-asserted-by":"crossref","unstructured":"Kodarahmian M, Amidi F, Moini A, Kashani L, Shabani Nashtaei M, Pazhohan A, et al. The modulating effects of Resveratrol on the expression of MMP-2 and MMP-9 in endometriosis women: a randomized exploratory trial. Gynecological Endocrinology. 2019;35(8):719\u201326.","DOI":"10.1080\/09513590.2019.1576612"},{"issue":"12","key":"4049_CR103","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.3390\/genes11121509","volume":"11","author":"LM De Jong","year":"2020","unstructured":"De Jong LM, Jiskoot W, Swen JJ, Manson ML. Distinct Effects of Inflammation on Cytochrome P450 Regulation and Drug Metabolism: Lessons from Experimental Models and a Potential Role for Pharmacogenetics. Genes. 2020;11(12):1509.","journal-title":"Genes"},{"issue":"10","key":"4049_CR104","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1124\/dmd.122.000926","volume":"50","author":"KF Chen","year":"2022","unstructured":"Chen KF, Jones HM, Gill KL. Physiologically Based Pharmacokinetic Modeling To Predict Drug-Biologic Interactions with Cytokine Modulators: Are These Relevant and Is Interleukin-6 Enough? Drug Metab Dispos. 2022;50(10):1322\u201331.","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"4049_CR105","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41588-022-01254-1","volume":"55","author":"MAS Fonseca","year":"2023","unstructured":"Fonseca MAS, Haro M, Wright KN, Lin X, Abbasi F, Sun J, et al. Single-cell transcriptomic analysis of endometriosis. Nat Genet. 2023;55(2):255\u201367.","journal-title":"Nat Genet"},{"issue":"1","key":"4049_CR106","doi-asserted-by":"publisher","first-page":"11539","DOI":"10.1038\/s41467-025-66706-8","volume":"16","author":"Y Qi","year":"2025","unstructured":"Qi Y, Chen X, Zheng S, Wu T, Li Z, Cheng J, et al. Single-cell and spatially resolved omics reveal transcriptional and metabolic signatures of ovarian endometriomas. Nat Commun. 2025;16(1):11539.","journal-title":"Nat Commun"},{"issue":"1","key":"4049_CR107","doi-asserted-by":"publisher","first-page":"38682","DOI":"10.1038\/s41598-025-22598-8","volume":"15","author":"C Wojty\u0142a","year":"2025","unstructured":"Wojty\u0142a C, Kupcewicz B, To\u0142wi\u0144ski I, Samborowska E, Radkiewicz M, Ja\u017awiec R, et al. Metabolome analysis as a potential source of endometriosis biomarkers with the use of multiomics approach in its diagnosis. Sci Rep. 2025;15(1):38682.","journal-title":"Sci Rep"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04049-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-026-04049-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04049-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T13:55:00Z","timestamp":1776088500000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-026-04049-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":107,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["4049"],"URL":"https:\/\/doi.org\/10.1007\/s11095-026-04049-9","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"assertion":[{"value":"16 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}